Nonclinical and clinical experiences with CPP-based self-assembling peptide systems in topical drug development.

Considerations in rational designs of CPP-based transcutaneous delivery systems are described. Impact of design considerations of nonclinical and clinical results are presented in detail.

[1]  J. Carruthers,et al.  The evolution of botulinum neurotoxin type A for cosmetic applications , 2007, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[2]  A. Matarasso,et al.  Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. , 2001, Plastic and reconstructive surgery.

[3]  M. Naumann,et al.  Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. , 1998, Archives of dermatology.

[4]  F. Heinen,et al.  Botulinum Toxin A , 1997 .

[5]  M. Naumann,et al.  Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial , 2001, BMJ : British Medical Journal.

[6]  M. Binder,et al.  Botulinum A toxin injection in Focal hyperhidrosis , 1996, The British journal of dermatology.

[7]  M. Hallett.  One man's poison--clinical applications of botulinum toxin. , 1999, The New England journal of medicine.

[8]  A. B. Scott,et al.  Botulinum toxin injection of eye muscles to correct strabismus. , 1981, Transactions of the American Ophthalmological Society.

[9]  K. Aoki,et al.  Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions , 2001, European journal of neurology.

[10]  H. Schutta,et al.  Botulinum toxin–a possible new treatment for axillary hyperhidrosis , 1996, Clinical and experimental dermatology.

[11]  N. Lowe,et al.  Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. , 2002, Journal of the American Academy of Dermatology.

[12]  J. Carruthers,et al.  Treatment of glabellar frown lines with C. botulinum-A exotoxin. , 1992, The Journal of dermatologic surgery and oncology.

[13]  B. Ascher,et al.  Double‐Blind, Randomized, Placebo‐Controlled, Dose‐Response Study of the Safety and Efficacy of Botulinum Toxin Type A in Subjects with Crow's Feet , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[14]  F. Farzaneh,et al.  Protein transduction: an alternative to genetic intervention? , 2001, Gene Therapy.

[15]  ndres,et al.  BOTULINUM TOXIN A FOR AXILLARY HYPERHIDROSIS ( EXCESSIVE SWEATING ) , 2001 .

[16]  R. Glogau.  Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[17]  J. Carruthers,et al.  Botulinum toxin type A. , 2005, Journal of the American Academy of Dermatology.

[18]  K. Aoki,et al.  A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. , 2001, Toxicon : official journal of the International Society on Toxinology.

[19]  J. Carruthers,et al.  Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. , 2004, Plastic and reconstructive surgery.

[20]  C. Montecucco,et al.  Internalization and mechanism of action of clostridial toxins in neurons. , 2005, Neurotoxicology.

[21]  J. Dutton,et al.  Botulinum toxin in ophthalmology. , 2007, Survey of ophthalmology.